Lindbrook Capital’s Atea Pharmaceuticals AVIR Stock Holding History

Lindbrook Capital’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-378	Closed	-$1.41K	–	2693
2023 Q2	$1.41K	Buy	378 +67	+22%	+$251	﹤0.01%	2286
2023 Q1	$1.04K	Buy	311 +4	+1%	+$16	﹤0.01%	2444
2022 Q4	$1.48K	Buy	307 +18	+6%	+$91	﹤0.01%	2362
2022 Q3	$2K	Sell	289 -24	-8%	-$184	﹤0.01%	1987
2022 Q2	$2K	Buy	+313	New	+$2.14K	﹤0.01%	1905
2022 Q1	–	Sell	-50	Closed	–	–	2469
2021 Q4	$0	Buy	+50	New	+$779	﹤0.01%	2069

Other funds holding AVIR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lindbrook Capital's AVIR Position: Q3 2023 in Review

Lindbrook Capital sold out of Atea Pharmaceuticals (AVIR) in Q3 2023, closing a stake of 378 shares — an estimated $1.41K sold.

Lindbrook Capital first reported a position in AVIR in Q4 2021 and held it in 6 quarters. The position peaked at $2K in Q3 2022. 119 funds tracked by Wall St. Rank hold AVIR as of Q3 2023.

Lindbrook Capital reported no remaining Atea Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Lindbrook Capital sold 378 Atea Pharmaceuticals shares in Q3 2023, an estimated $1.41K.
Lindbrook Capital first reported a position in Atea Pharmaceuticals in Q4 2021 and held it in 6 quarters.
Lindbrook Capital's Atea Pharmaceuticals position peaked at $2K in Q3 2022.
119 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2023.

Based on Lindbrook Capital's 13F filing for Q3 2023, filed 25 Oct 2023.